Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-302 in previously untreated advanced or metastatic urothelial cancer
jRCT2031200284Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Japan-specific safety run-in adverse events including dose-limiting toxicities, Japan-specific safety run-in laboratory abnormalities and 3 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031200284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200284.